Form 4: Foghorn Therapeutics Director Reports Stock Option Grant

Stuart Duty, a Director at Foghorn Therapeutics Inc., reported the acquisition of 28,000 stock options with an exercise price of $4.08.

Summary

• Stuart Duty, a Director of Foghorn Therapeutics Inc. (FHTX), has reported the acquisition of stock options.
• The transaction, dated June 24, 2026, involves 28,000 stock options with an exercise price of $4.08 per share.
• These options are exercisable and expire on June 23, 2036.
• The options vest in full on the first anniversary of the grant date, contingent upon continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard stock option grant to a director rather than a significant financial event or change in company performance.

Positives

• Director Stuart Duty has been granted a significant number of stock options (28,000), indicating potential future value tied to the company's performance.
• The grant of options suggests management's and the board's confidence in the company's future prospects.
• The exercise price of $4.08 is set, providing a clear benchmark for potential profit upon vesting and exercise.

Negatives

• The options are not immediately exercisable and are subject to a vesting period, meaning the reporting person cannot realize value until the vesting conditions are met.
• The value of the options is entirely dependent on the future stock price of Foghorn Therapeutics, which carries inherent market risk.

Risks

• The primary risk is that the company's stock price may not appreciate sufficiently to make the exercise of these options profitable.
• Continued service as a director is a condition for vesting, implying a risk of forfeiture if the reporting person steps down or is removed from the board.
• Market volatility and industry-specific challenges could negatively impact Foghorn Therapeutics' stock performance.

Future Outlook

The future outlook for the value of these options is contingent on the company's stock performance and the reporting person's continued service.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive and board compensation with shareholder interests and incentivizing long-term company growth.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, as the value of the options increases with the company's stock price. However, it also represents potential future dilution if options are exercised.
• Employees: While not directly impacting employees, such grants can be seen as a positive signal of board confidence, potentially boosting morale.
• Management: The grant reinforces the incentive structure for key leadership to drive company performance.

Next Steps

• The reporting person must continue to serve as a director for the options to vest.
• The options will become exercisable on the first anniversary of the grant date.
• The reporting person may choose to exercise the options at any time between the vesting date and the expiration date, provided the stock price is favorable.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, SEC Filing, Beneficial Ownership, Grant Date, Vesting Schedule